|
1
|
Rha SE, Jung SE, Lee KH, Ku YM, Byun JY
and Lee JM: CT and MR imaging findings of endocrine tumor of the
pancreas according to WHO classification. Eur J Radiol. 62:371–377.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Modlin IM and Sandor A: An analysis of
8305 cases of carcinoid tumors. Cancer. 79:813–829. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Phan GQ, Yeo CJ, Hruban RH, Lillemoe KD,
Pitt HA and Cameron JL: Surgical experience with pancreatic and
peripancreatic neuroendocrine tumors: review of 125 patients. J
Gastrointest Surg. 2:472–482. 1998.
|
|
4
|
Hochwald SN, Zee S, Conlon KC, Colleoni R,
Louie O, Brennan MF and Klimstra DS: Prognostic factors in
pancreatic endocrine neoplasms: an analysis of 136 cases with a
proposal for low-grade and intermediate-grade groups. J Clin Oncol.
20:2633–2642. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heitz PU, Komminoth P, Perren A, Klimstra
DS, Dayal Y, Bordi C, Lechagon J, Centeno BA and Kloppel G: Tumours
of the endocrine pancreas. Pathology and Genetics of Tumours of
Endocrine Organs (World Health Organization Classification of
Tumours). DeLellis RA, Lloyd RV, Heitz PU and Eng C: IARC Press;
Lyon: pp. 177–182. 2004
|
|
6
|
Capella C, Heitz PU, Hofler H, Solcia E
and Kloppel G: Revised classification of neuroendocrine tumors of
the lung, pancreas and gut. Digestion. 55:11–23. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bettini R, Boninsegna L, Mantovani W,
Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A
and Falconi M: Prognostic factors at diagnosis and value of WHO
classification in a mono-institutional series of 180
non-functioning pancreatic endocrine tumours. Ann Oncol.
19:903–908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schmitt AM, Anlauf M, Rousson V, Schmid S,
Kofler A, Riniker F, Bauersfeld J, Barghorn A, Probst-Hensch NM,
Moch H, Heitz PU, Kloeppel G, Komminoth P and Perren A: WHO 2004
criteria and CK19 are reliable prognostic markers in pancreatic
endocrine tumors. Am J Surg Pathol. 31:1677–1682. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferrone CR, Tang LH, Tomlinson J, Gonen M,
Hochwald SN, Brennan MF, Klimstra DS and Allen PJ: Determining
prognosis in patients with pancreatic endocrine neoplasms: can the
WHO classification system be simplified? J Clin Oncol.
25:5609–5615. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reske SN and Kotzerke J: FDG-PET for
clinical use. Results of the 3rd German Interdisciplinary Consensus
Conference, ‘Onko-PET III’, 21 July and 19 September 2000. Eur J
Nucl Med. 28:1707–1723. 2001.
|
|
11
|
Bombardieri E, Aktolun C, Baum RP,
Bishof-Delaloye A, Buscombe J, Chatal JF, Maffioli L, Moncayo R,
Mortelmans L and Reske SN: FDG-PET: procedure guidelines for tumour
imaging. Eur J Nucl Med Mol Imaging. 30:BP115–124. 2003.PubMed/NCBI
|
|
12
|
Adams S, Baum R, Rink T, Schumm-Drager PM,
Usadel KH and Hor G: Limited value of fluorine-18
fluorodeoxyglucose positron emission tomography for the imaging of
neuroendocrine tumours. Eur J Nucl Med. 25:79–83. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pasquali C, Rubello D, Sperti C, Gasparoni
P, Liessi G, Chierichetti F, Ferlin G and Pedrazzoli S:
Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron
emission tomography detect tumors with poor prognosis and
aggressive behavior? World J Surg. 22:588–592. 1998. View Article : Google Scholar
|
|
14
|
Eriksson B, Bergstrom M, Orlefors H,
Sundin A, Oberg K and Langstrom B: Use of PET in neuroendocrine
tumors. In vivo applications and in vitro studies. Q J Nucl Med.
44:68–76. 2000.PubMed/NCBI
|
|
15
|
Eriksson B, Bergstrom M, Sundin A, Juhlin
C, Orlefors H, Oberg K and Langstrom B: The role of PET in
localization of neuroendocrine and adrenocortical tumors. Ann NY
Acad Sci. 970:159–169. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pawlikowski M and Melen-Mucha G:
Somatostatin analogs from new molecules to new applications. Curr
Opin Pharmacol. 4:608–613. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pacak K, Eisenhofer G and Goldstein DS:
Functional imaging of endocrine tumors: role of positron emission
tomography. Endocr Rev. 25:568–580. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sperti C, Pasquali C, Chierichetti F,
Ferronato A, Decet G and Pedrazzoli S: 18-Fluorodeoxyglucose
positron emission tomography in predicting survival of patients
with pancreatic carcinoma. J Gastrointest Surg. 7:953–959. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vansteenkiste JF, Stroobants SG, Dupont
PJ, De Leyn PR, Verbeken EK, Deneffe GJ, Mortelmans LA and Demedts
MG: Prognostic importance of the standardized uptake value on
(18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in
non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung
Cancer Group. J Clin Oncol. 17:3201–3206. 1999.
|
|
20
|
Downey RJ, Akhurst T, Gonen M, Vincent A,
Bains MS, Larson S and Rusch V: Preoperative F-18
fluorodeoxyglucose-positron emission tomography maximal
standardized uptake value predicts survival after lung cancer
resection. J Clin Oncol. 22:3255–3260. 2004. View Article : Google Scholar
|
